of Core Service Plan: The primary purpose ofthe Molecular Profiling and Pathology (MPP) Core is to provide the investigators in this POl with a centralized and coordinated resource for the analysis of human lung cancer samples and animal model tissues using morphologic and high throughput molecular methods (histopathology, immunohistochemistry, in situ hybridization, genomic and proteomic analyses). The MPP Core functions within this POl are grouped into four logically connected Aims or activities. 1. Procurement of human lung cancer tissues for validation studies. The Core will serve as the centralized resource for validation studies using human lung cancer samples procured under several MKSCC IRBapproved protocols. For rebiopsy protocols (non-therapeutic rebiopsy after treatment initiation or rebiopsy upon progression due to presumed acquired resistance), the Gore will also serve as the main tissue repository. 2. Pathology review &analysis. The MPP core will provide expert histologic and cytologic evaluation and classification of all human lung cancer specimens used in the POl, including morphologybased assays (IHC, GISH, FISH). The MPP will also provide expert histopathologic review of lung tumors in mouse models as well as xenografted human tumors. 3. Genotyping of human lung cancer tissues for validation studies. The MPP Gore has established and is further developing prospective genotyping efforts to provide extended mutational annotation of its human lung tumor resources that is critical for rational, welldesigned validation studies biologically relevant to specific leads arising from the Research Projects. 4. Coordination of validation studies using fully annotated human lung cancer tissues. The activities described in Aims 1-3 will provide a rich collection of rigorously classified human lung cancer tissues annotated for key lung cancer genes. Studies needed to validate the discoveries generated by the individual research projects in human lung cancer tissues will be performed in or coordinated by Core personnel. Robust platforms are established for DNA, RNA and protein analytes, with the specific validation analyses being determined by the questions to be answered by the individual Research Projects.

Public Health Relevance

The MPP core will serve a critical validation function, relating the findings ofthe Research Projects to human lung carcinomas and placing them in the context of key clinical, pathologic, mutational, and genomic parameters. Consistency of diagnostic criteria and technical platforms will ensure data comparability and data exchange between projects.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA129243-07
Application #
8563897
Study Section
Special Emphasis Panel (ZCA1-RPRB-J)
Project Start
Project End
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
7
Fiscal Year
2013
Total Cost
$199,697
Indirect Cost
$69,101
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Yu, Helena A; Arcila, Maria E; Harlan Fleischut, Megan et al. (2014) Germline EGFR T790M mutation found in multiple members of a familial cohort. J Thorac Oncol 9:554-8
Meador, Catherine B; Micheel, Christine M; Levy, Mia A et al. (2014) Beyond histology: translating tumor genotypes into clinically effective targeted therapies. Clin Cancer Res 20:2264-75
Valiente, Manuel; Obenauf, Anna C; Jin, Xin et al. (2014) Serpins promote cancer cell survival and vascular co-option in brain metastasis. Cell 156:1002-16
de Bruin, Elza C; Cowell, Catherine; Warne, Patricia H et al. (2014) Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer. Cancer Discov 4:606-19
Rekhtman, Natasha; Borsu, Laetitia; Reva, Boris et al. (2014) Unsuspected collision of synchronous lung adenocarcinomas: a potential cause of aberrant driver mutation profiles. J Thorac Oncol 9:e1-3
Yu, H A; Arcila, M E; Hellmann, M D et al. (2014) Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing. Ann Oncol 25:423-8
Lovly, Christine M; McDonald, Nerina T; Chen, Heidi et al. (2014) Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer. Nat Med 20:1027-34
Yu, Helena A; Riely, Gregory J; Lovly, Christine M (2014) Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors. Clin Cancer Res 20:5898-907
Pirazzoli, Valentina; Nebhan, Caroline; Song, Xiaoling et al. (2014) Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1. Cell Rep 7:999-1008
Haq, Rizwan; Fisher, David E; Widlund, Hans R (2014) Molecular pathways: BRAF induces bioenergetic adaptation by attenuating oxidative phosphorylation. Clin Cancer Res 20:2257-63

Showing the most recent 10 out of 59 publications